Evidence map›Paper›PMID 42851000›Full record

ArticleJournal of the International AIDS Society2026

Specification and Causal Pathway Diagramming of Implementation Strategies to Support Development of Access-Enhancing Injectable HIV Treatment Programmes at Eight Diverse Health Clinics Across the United States.

Kathrine Meyers, Nadia Nguyen, Charlie Ferrusi, Jason Zucker, Sarit A Golub, Bryan A Kutner, Mamta Karani, Cody A Chastain, Marilyn Blasingame, Moya Brown-Lopez and 14 more

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Kathrine MeyersAaron Diamond AIDS Research Center, Columbia University Irving Medical Center, New York City, New York, USA.
Nadia NguyenAaron Diamond AIDS Research Center, Columbia University Irving Medical Center, New York City, New York, USA.ORCID https://orcid.org/0000-0002-4376-3783
Charlie FerrusiAaron Diamond AIDS Research Center, Columbia University Irving Medical Center, New York City, New York, USA.ORCID https://orcid.org/0009-0003-2536-7917
Jason ZuckerDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York City, New York, USA.
Sarit A GolubHunter College of the City University of New York, New York City, New York, USA.
Bryan A KutnerMontefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, USA.
Mamta KaraniNew York City Health Department, Queens, New York, USA.
Cody A ChastainDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Marilyn BlasingameNew York City Health Department, Queens, New York, USA.
Moya Brown-LopezNew York City Health Department, Queens, New York, USA.
Jennifer BurdgeDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Delivette CastorDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York City, New York, USA.ORCID https://orcid.org/0000-0002-0988-9489
Caroline CarnevaleNewYork-Prebysterian Hospital, New York City, New York, USA.
Jenna EldibNewYork-Prebysterian Hospital, New York City, New York, USA.
Elizabeth FuruyaHunter College of the City University of New York, New York City, New York, USA.
Omolola AkoloBaltimore City Health Department, Baltimore, Maryland, USA.
Kelly BastienSunshine Care Center, Florida Department of Health, Orlando, Florida, USA.
Melissa CurryAbounding Prosperity, Inc., Dallas, Texas, USA.
Will HoltCoastal Family Health Center, Biloxi, Mississippi, USA.
Bijou R HuntSinai Infectious Disease Center, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-6787-295X
Shin LyPositive Impact Health Center, Decatur, Georgia, USA.
Carlotta StarksJack Martin Fund Center, Mount Sinai Institute for Advanced Medicine, New York City, New York, USA.
Fabriel TorresSan Antonio AIDS Foundation, San Antonio, Texas, USA.
Marlene MatoskyU.S. Department of Health and Human Services, Health Resources and Services Administration, Rockville, Maryland, USA.

Funding

HRSA HHS
6 · The paper itself

Abstract

introductionLong-acting injectable antiretroviral therapy (LAI ART) represents a transformative development in HIV care because it may mitigate longstanding barriers that contribute to gaps in health outcomes. Providing LAI ART to people not consistently on HIV treatment or lacking treatment options requires intentional programme planning to overcome implementation barriers, without which only well-resourced patients benefit, worsening health outcome gaps. The ALAI UP Project delivered clinic-level implementation strategies to support eight clinics across Ending the HIV Epidemic jurisdictions to implement injectable cabotegravir and rilpivirine (iCAB/RPV).

methodsWe specified seven implementation strategies and assessed their impact on clinic achievement of three key programme outcomes: (a) access to information about iCAB/RPV for all patients regardless of clinical eligibility; (b) access to iCAB/RPV regardless of healthcare coverage; and (c) access to iCAB/RPV for those who can clinically benefit the most, including patients who are unable to achieve durable viral suppression on oral ART for reasons other than cabotegravir or rilpivirine resistance. Implementation strategies were delivered from March 2023 through February 2025, and results are reported at the end of year 2 of the 3-year project. We developed causal pathway diagrams (CPDs) for each strategy, identifying determinants, preconditions, moderators, mechanisms and outcomes.

resultsALAI UP strategies supported clinic progress towards all three outcomes: six clinics had partially or fully achieved access to information about iCAB/RPV for all patients, seven clinics had partially or fully achieved access to iCAB/RPV for patients regardless of healthcare coverage, and six clinics had provided access to iCAB/RPV for those who could benefit the most clinically. By developing CPDs for each strategy, we explicated how strategies operated across different clinical contexts. Through this process, we identified mechanisms of action that needed to be activated, moderators that impacted strategy strength and preconditions that needed to be in place for the strategy to function. These insights informed changes to strategies in the final year of the project.

conclusionThis work demonstrates that applying implementation science tools to service delivery projects can enhance precision and reproducibility of strategies, identify intervention points for improving strategies when mechanisms are not activated, and clarify hypothesized causal pathways testable in future hybrid effectiveness-implementation trials.

Indexed as

Anti-HIV AgentsHealth Services AccessibilityHIV InfectionsPyridonesRilpivirineAdherence InterventionsDiketopiperazinesHumansInjectionsUnited StatesAnti-HIV AgentscabotegravirDiketopiperazinesPyridonesRilpivirineHIVimplementation sciencelong‐acting injectablestreatment

Identifiers

PMID42851000
PMCPMC13650423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.